Introduction {#sec1}
============

Glioblastoma is the most common lethal primary brain tumor.[@bib1] Although given aggressive surgery with adjuvant radiotherapy and chemotherapy, glioblastoma patients still show poor prognosis.[@bib2] One of the reasons is that the intrinsic tumor cells in the tumor tissue invade the surrounding parenchyma, which leads to the inadequacy of surgical removal. Moreover, resistance to traditional and targeted therapy results in the complexity of glioblastoma treatment.[@bib3] Therefore, it is urgent to explore an effective molecular targeted therapy.

Long non-coding RNAs (lncRNAs) belong to recently discovered non-coding genes, which are transcribed throughout the genome.[@bib4] Accumulating evidence suggests that lncRNAs may be related with the modulation of various aspects of tumor biology. Remarkably, emerging reports have shown that small nucleolar RNA host genes (SNHGs) are involved in diverse cellular processes.[@bib5] For example, SNHG1 induces the malignant progression of human hepatocellular carcinoma cells and predicts poor prognosis.[@bib6] SNHG15 is upregulated in human gastric cancer and promotes malignancy.[@bib7] SNHG12 can promote the tumorigenesis of human osteosarcoma cells.[@bib8] However, the expression and function of SNHG12 in gliomas remain largely unknown.

RNA binding proteins (RBPs) are ubiquitously expressed in various tumors. Multiple reports have demonstrated RBPs are involved in the regulation of tumor cells' biological process. Galectin-3 is highly expressed in pancreatic cancer cells and stabilizes MUC4 mRNA.[@bib9] Inhibition of mRNA-binding protein human antigen R (HuR) sensitizes colorectal cancer cells to ionizing radiation.[@bib10] Dysregulation of TAR-DNA binding protein 43 (TDP43) confers to various disorders such as amyotrophic lateral sclerosis, brain ischemia, and Alzheimer's disease.[@bib11] Also, dysregulation of TDP43 contributes to the progression of neuroblastoma and breast cancer.[@bib12] However, the profiling of TDP43 in glioma remains incompletely delineated.

MicroRNAs (miRNAs) are a group of short-chain non-coding RNAs, which regulate the expression of target genes mainly by combining perfectly or imperfectly with the 3′ UTR of target genes.[@bib13] Recent studies have proven the existence of competing endogenous RNAs (ceRNAs). miRNA competitively binds to transcripts such as mRNA and lncRNA through the miRNA response element (MRE), regulating their respective expression levels, thus affecting their functions. In recent years, researchers have confirmed that lncRNAs serve as ceRNAs in the genesis and progression of tumors by regulating gene expression.[@bib14] miR-195 is involved in the occurrence and progression of various tumors. miR-195 is downregulated in human breast cancer and exerts tumor-suppressive function.[@bib15] Further, miR-195 acts as a tumor-suppressive gene via impairing human cervical cancer cell growth.[@bib16] miR-195 inhibited the proliferation of human glioma cells by targeting cyclin D1 and E1.[@bib17] In addition, it has been found to be downregulated in glioma tissues, and inhibits glioma cell proliferation and invasion.[@bib18] But the detailed function of miR-195 in glioma has not been explored.

The SOX gene family consists of SRY (sex-determining region Y chromosome)-related genes, which encode a series of SOX (SRY-related HMG-box) family transcripts. SOX genes play a crucial role in the regulation of sex determination, osseous development, hemocyte formation, nervous system development, and crystalline development.[@bib19] SOX5, a member of the SOX gene family, is expressed in normal spermoblasts, neurocytes, oligodendrocytes, and chondrocytes.[@bib20], [@bib21], [@bib22] Emerging evidence has proven that SOX5 is related to the occurrence and progression of tumors. SOX5 is overexpressed in esophageal squamous cell carcinoma.[@bib23] Overexpressed SOX5 is a biomarker and induces metastasis and poor prognosis of breast cancer. There has been a dispute about the expression of SOX5 in glioma cells and tissues. SOX5 was found underexpressed in platelet-derived growth factor B (PDGFB)-induced mouse glioma tissues,[@bib24] while another study shows it is overexpressed in human glioma tissues.[@bib25] Hence, the effect and mechanism of SOX5 in the occurrence and progression of human glioma need to be investigated.

In the present study, we profiled TDP43, SNHG12, miR-503, and SOX5 expressions in glioma tissues and cells. Moreover, roles in regulating glioma malignant progression and interactions among TDP43, SNHG12, miR-503, and SOX5 were examined. These results may offer an alternative strategy and targets for glioma therapy.

Results {#sec2}
=======

TDP43 Plays an Oncogenic Role in Glioma Cells via Stabilizing SNHG12 {#sec2.1}
--------------------------------------------------------------------

The expression of TDP43 in glioma tissues and cells was detected using western blot ([Figure 1](#fig1){ref-type="fig"}A) (normal brain tissues \[NBTs\], low-grade glioma tissues \[LGGT\], and high-grade glioma tissues \[HGGTs\]).Using lncRNAs microarray, we found SNHG12 was significantly downregulated in glioma cells treated with sh-TDP43 ([Figure S1](#mmc1){ref-type="supplementary-material"}A). Therefore, we hypothesized that SNHG12 was involved in TDP43-mediated regulation on glioma cells. Further, the expression of SNHG12 in glioma tissues and cells was investigated by real-time qPCR and fluorescence *in situ* hybridization (FISH). As [Figure 1](#fig1){ref-type="fig"}B shows, SNHG12 expression was positively correlated with the progression of glioma pathological grades. SNHG12 was significantly upregulated in glioma cell lines compared with normal human astrocytes ([Figure 1](#fig1){ref-type="fig"}C). Also, SNHG12 was found to be located in both nucleus and cytoplasm in the cells ([Figure 1](#fig1){ref-type="fig"}D). Therefore, we hypothesized that TDP43 and SNHG12 might exert key roles in glioma malignant progression. Glioma cells stably expressing sh-TDP43 and sh-SNHG12 were established to investigate the function of TDP43 and SNHG12. As [Figure 1](#fig1){ref-type="fig"}E shows, inhibition of TDP43 or SNHG12 led to a decrease in proliferation of glioma cells. In addition, inhibition of TDP43 combined with inhibition of SNHG12 significantly impeded glioma cell growth. Flow cytometry analysis was used to determine the effect of TDP43 and SNHG12 on apoptosis of glioma cells. As shown in [Figure 1](#fig1){ref-type="fig"}F, knockdown of SNHG12 markedly enhanced apoptosis of glioma cells compared with the sh-negative control (NC) group. Further, transwell assays results showed that glioma cells treated with sh-TDP43 and sh-SNHG12 exhibited weaker migration and invasion abilities ([Figure 1](#fig1){ref-type="fig"}G).Figure 1TDP43 and SNHG12 Served as Oncogenes in Glioma Cells(A) Western blot was used to determine TDP43 expression in glioma tissues (left) and cells (right). Data are presented as the mean ± SD. (n = 4, NBTs; n = 4, grade I; n = 5, grade II; n = 13, grade III; n = 17, grade IV. Left: \*\*p \< 0.01 versus nontumorous brain tissues; ^\#\#^p \< 0.01 versus low-grade glioma tissues. Right: \*\*p \< 0.01 versus normal human astrocytes. (B) Real-time qPCR was used to detect expression levels of SNHG12 in glioma tissues of different grades and NBTs. Data are presented as the mean ± SD (n = 5, NBTs group; n = 15, each grade of glioma tissues). \*\*p \< 0.01 versus NBTs group. (C) Expression levels of SNHG12 in human normal astrocytes and glioma cell lines. Data are presented as the mean ± SD (n = 5 in each group). \*\*p \< 0.01 versus normal human astrocytes group. (D) FISH was performed to investigate expression and location of SNHG12 in normal human astrocytes (NHA) and U87 and U251 glioma cells (green, SNHG12; blue, DAPI nuclear staining). Scale bars represent 20 μm. (E) CCK-8 assay was conducted to investigate the effect of TDP43 and SNHG12 inhibition on proliferation in U87 and U251 cells. (F) Flow cytometry analysis of U87 and U251 cells with the altered expression of TDP43 and SNHG12. (G) Quantification number of migration and invasion cells treated with inhibition of TDP43 and SNHG12. Representative images and accompanying statistical plots were presented. Data are presented as the mean ± SD (n = 5 in each group). \*p \< 0.05 versus sh-NC group (empty vector); \*\*p \< 0.01 versus sh-NC group (empty vector); ^*\#*^p *\<* 0.05 versus sh-TDP43 group; ^*&*^p *\<* 0.05 versus sh-SNHG12 group. Scale bars represent 40 μm.

Having confirmed that both TDP43 and SNHG12 exerted oncogenic roles in glioma cells, we further investigated the correlation between TDP43 and SNHG12. We predicted TDP43 might bind to SNHG12 with the help of bioinformatics software (Starbase). RNA immunoprecipitation (RIP) results showed that enrichment of SNHG12 was higher in the anti-TDP43 group compared with the anti-IgG group ([Figure 2](#fig2){ref-type="fig"}A). Also, RNA pull-down assays demonstrated that SNHG12 bound with TDP43 ([Figure 2](#fig2){ref-type="fig"}B). In addition, we detected the expression of SNHG12 in cells treated with sh-TDP43. As shown in [Figure 2](#fig2){ref-type="fig"}C, SNHG12 expression was significantly decreased in the sh-TDP43 group compared with the sh-NC group. We further explored the underlying mechanism where TDP43 bound to SNHG12 and modulated its expression. As shown in [Figure 2](#fig2){ref-type="fig"}D, the half-life of SNHG12 was significantly reduced in sh-TDP43 cells treated with actinomycin D. These results indicated that TDP43 facilitated glioma cells malignant progression by stabilizing SNHG12.Figure 2TDP43 Bound with SNHG12 and Stabilized SNHG12, and Reintroduction of miR-195 Hindered Glioma Cell Malignancy(A) SNHG12 was identified in the TDP43 complex. SNHG12 enrichment was measured using real-time qPCR. Data represent mean ± SD (n = 5 in each group). \*\*p \< 0.01 versus anti-IgG group. (B) TDP43 and GAPDH protein levels in immunoprecipitation with SNHG12 RNA were evaluated by western blots. The expression levels of TDP43 and GAPDH proteins are shown. (C) Real-time qPCR analysis for TDP43 regulating SNHG12 expression in U87 and U251 cells. Data are presented as the mean ± SD (n = 5 in each group). \*p \< 0.05 versus sh-NC group. (D) The graph represents the relative levels of the SNHG12 at the different actinomycin D treatment times in the control group, sh-NC group, and sh-TDP43 group. (E) FISH was applied to investigate expression and location of miR-195 in human normal astrocytes (NHA) and glioma cell lines (red, miR-195; blue, DAPI nuclear staining). Scale bars represent 20 μm. (F) CCK-8 assay was conducted to determine the effect of miR-195 on proliferation in U87 and U251 cells. (G) Flow cytometry analysis of U87 and U251 cells with the altered expression of miR-195. (H) Quantification number of migration and invasion cells treated with different expression levels of miR-195. Representative images and accompanying statistical plots were presented. Scale bars represent 40 μm. Data are presented as the mean ± SD (n = 5 in each group). \*p \< 0.05 versus pre-NC group (empty vector); ^*\#*^p *\<* 0.05 versus anti-NC group (empty vector).

miR-195 Restrains Cell Proliferation, Migration, and Invasion while Promoting Apoptosis of Glioma Cells {#sec2.2}
-------------------------------------------------------------------------------------------------------

miR-195 is identified as a tumor suppressor in various cancers. An earlier report showed miR-195 was downregulated in gliomas.[@bib18] Using microRNAs microarray, we proved miR-195 was one of the downregulated genes in glioma cells treated with sh-SNHG12 ([Figure S1](#mmc1){ref-type="supplementary-material"}B). FISH assay was conducted to reveal the expression and location of miR-195 in glioma cells ([Figure 2](#fig2){ref-type="fig"}E). Similar to SNHG12, miR-195 was also located in both the nucleus and the cytoplasm in the cells. To investigate the detailed function of miR-195 in glioma cells, effects of overregulated or downregulated miR-195 on glioma cells were determined. As shown in [Figure 2](#fig2){ref-type="fig"}F, restoration of miR-195 significantly decreased proliferation of glioma cells compared with the pre-NC group. Flow cytometry analysis result showed overexpressed miR-195 induced apoptosis of glioma cells ([Figure 2](#fig2){ref-type="fig"}G). Moreover, overexpression of miR-195 significantly reduced migrating and invading cell numbers compared with the pre-NC group ([Figure 2](#fig2){ref-type="fig"}H). As expected, our results showed that miR-195 exerted key roles in the regulation of glioma cell progression.

miR-195 Targets SNHG12, and Its Expression Is Negatively Correlated with SNHG12 {#sec2.3}
-------------------------------------------------------------------------------

Using bioinformatics databases (Starbase), we recognized SNHG12 as a putative target of miR-195. We first measured the expression of miR-195 in glioma cells transfected with sh-SNHG12. Expression of miR-195 was markedly upregulated in cells treated with sh-SNHG12 ([Figure 3](#fig3){ref-type="fig"}A). On the contrary, overexpression of miR-195 significantly reduced the expression of SNHG12 ([Figure 3](#fig3){ref-type="fig"}B). Dual-luciferase gene reporter assays were conducted to further clarify the interaction between SNHG12 and miR-195. As shown in [Figure 3](#fig3){ref-type="fig"}D, luciferase activity in the SNHG12-WT (wild-type)+pre-miR-195 group was significantly impaired compared with that in the control group, whereas SNHG12-Mut groups were not affected. These results support our hypothesis that miR-195 binds to SNHG12 in a sequence-specific manner.Figure 3Knockdown of SNHG12 Impaired Malignant Biological Behaviors of Glioma Cells by Inducing miR-195 Expression(A) Real-time qPCR analysis for TDP43 and SNHG12 regulating miR-195 expression in U87 and U251 cells. Data are presented as the mean ± SD (n = 5 in each group). \*p \< 0.05 versus sh-NC group (empty vector); \*\*p \< 0.01 versus sh-NC group (empty vector); ^\#^p \< 0.05 versus sh-TDP43 group; ^&^p \< 0.05 versus sh-SNHG12 group. (B) Real-time qPCR analysis for miR-195 modulating SNHG12 expression in U87 and U251 cells. Data are presented as the mean ± SD (n = 5 in each group). \*p \< 0.05 versus pre-NC group (empty vector); ^\#^p \< 0.01 versus anti-NC group (empty vector). (C) The predicted miR-195 binding site in SNHG12 (SNHG12-WT) and/or the designed mutant sequence (SNHG12-Mut) was indicated. (D) Luciferase reporter assay of HEK293 cells co-transfected with SNHG12-WT or SNHG12-Mut and miR-195 or the miR-195-NC. Data are presented as the mean ± SD (n = 5 in each group). *\**p *\<* 0.05 versus SNHG12-WT+pre-NC group. (E) miR-195 was identified in the SNHG12-RISC complex. SNHG12 and miR-195 enrichment were measured using real-time qPCR. Data represent mean ± SD (n = 5 in each group). \*\*p \< 0.01 versus anti-IgG group. (F) CCK-8 assay was used to determine the proliferative effect of SNHG12 and miR-195 on U87 and U251 cells. Data are presented as the mean ± SD (n = 5 in each group). \*p \< 0.05 versus sh-NC+pre-NC group (empty vectors). (G) Flow cytometry analysis of U87 and U251 with the altered expression of SNHG12 and miR-195. Data are presented as the mean ± SD (n = 5 in each group). \*\*p \< 0.01 versus sh-NC+pre-NC group (empty vectors). (H) Quantification number of migration and invasion cells with the altered expression of SNHG12 and miR-195. Representative images and accompanying statistical plots were presented. Data are presented as the mean ± SD (n = 5 in each group). \*p \< 0.05 versus sh-NC+pre-NC group (empty vectors). Scale bars represent 40 μm.

In addition, RIP assay was conducted to clarify whether SNHG12 and miR-195 were in the expected RNA-induced silencing complex (RISC). As shown in [Figure 3](#fig3){ref-type="fig"}E, expressions of SNHG12 and miR-195 were both increased in the anti-Ago2 group compared with that in anti-normal group. In the anti-miR-195 group, the expressions of SNH12 and miR-195 immunoprecipitated with Ago2 were lower than those in the control group, respectively. Collectively, these results indicated that miR-195 targeted SNHG12 in a sequence-specific manner, and there might be a reciprocal repression feedback loop between SNHG12 and miR-195.

miR-195 Modulates the Effect of SNHG12 Knockdown on Glioma Cells {#sec2.4}
----------------------------------------------------------------

To determine whether miR-195 could reverse the SNHG12-induced promotion effect on glioma cells, we rescued upregulation of miR-195 by SNHG12 inhibition using anti-miR-195 prior to the determination of malignant cell biological behaviors. As shown in [Figure 3](#fig3){ref-type="fig"}F, glioma cell proliferation was significantly attenuated in the sh-SNHG12+pre-miR-195 group compared with that in the sh-NC+pre-NC group. In addition, glioma cells treated with sh-SNHG12+pre-miR-195 showed a robustly increased apoptosis ratio ([Figure 3](#fig3){ref-type="fig"}G). Moreover, glioma cells transfected with sh-SNHG12 and pre-miR-195 exhibited weaker migration and invasion abilities ([Figure 3](#fig3){ref-type="fig"}H).

SOX5 Is Upregulated in Glioma Tissues and Cells, and Exerts Oncogenic Function in Glioma Cells {#sec2.5}
----------------------------------------------------------------------------------------------

Using bioinformatics databases (Starbase and TargetScan), we identified SOX5 as a putative downstream gene of miR-195. We first detected expression of SOX5 in glioma tissues and cells. As shown in [Figure 4](#fig4){ref-type="fig"}A, SOX5 mRNA expression was upregulated in glioma tissues compared with that in NBTs. Likewise, SOX5 mRNA expression was robustly upregulated in glioma U87 and U251 cells. We further investigated the effect of SOX5 on glioma cells. Glioma cells treated with SOX5 inhibition had a decreased proliferation ([Figure 4](#fig4){ref-type="fig"}B). Further, knockdown of SOX5 significantly promoted apoptosis of glioma cells compared with that in the SOX5^−^-NC group ([Figure 4](#fig4){ref-type="fig"}C). Similarly, inhibition of SOX5 significantly decreased migrating and invading glioma cell numbers ([Figure 4](#fig4){ref-type="fig"}D). These results suggested SOX5 favored malignant progression of glioma cells.Figure 4SOX5 Was Upregulated in Glioma Tissues and Cell Lines and Exerted Oncogenic Function in Glioma Cells(A) Left: SOX5 mRNA expression in glioma tissues. Data are presented as the mean ± SD (n = 5, NBTs; n = 4, grade I; n = 5, grade II; n = 13, grade III; n = 17, grade IV). \*\*p \< 0.01 versus NBTs group. Right: SOX5 mRNA expression in glioma cells. Data are presented as the mean ± SD (n = 5 in each group). \*\*p \< 0.01 versus normal human astrocytes group. (B) CCK-8 assay was used to explore the effect of SOX5 on proliferation in U87 and U251 cells. Data are presented as the mean ± SD (n = 5 in each group). *\**p *\<* 0.05 versus sh-NC group (empty vector). (C) Flow cytometry analysis of U87 and U251 with the altered expression of SOX5. Data are presented as the mean ± SD (n = 5 in each group). \*p \< 0.05 versus sh-NC group (empty vector). (D) Quantification number of migration and invasion cells with the altered expression of SOX5. Representative images and accompanying statistical plots were presented. Data are presented as the mean ± SD (n = 5 in each group). \*p \< 0.05 versus sh-NC group. Scale bars represent 40 μm.

miR-195 Targets SOX5 3′ UTR and Impairs Its Expression {#sec2.6}
------------------------------------------------------

Having confirmed SOX5 exerted oncogenic function in glioma cells, we further investigated whether SOX5 was involved in sh-TDP43-induced regulation of glioma cells. We first determined the expression level of SOX5 in cells treated with sh-TDP43 and sh-SNHG12. SOX5 protein expression was significantly decreased in sh-TDP43 and sh-SNHG12 groups ([Figure 5](#fig5){ref-type="fig"}A). Further, we detected SOX5 protein expression in cells treated with pre-miR-195 or anti-miR-195. As expected, SOX5 protein expression was diminished in the pre-miR-195 group, whereas miR-195 inhibition led to an increase in SOX5 protein expression ([Figure 5](#fig5){ref-type="fig"}B). Also, SOX5 was significantly downregulated in the sh-SNHG12+pre-miR-195 group ([Figure 5](#fig5){ref-type="fig"}C).Figure 5SOX5 Was a Target of miR-195 and Was Regulated by SNHG12 and miR-195(A) Western blot analysis of SOX5 regulated by TDP43 and SNHG12 is shown using GAPDH as endogenous control. Data are presented as the mean ± SD (n = 5 in each group). \*p \< 0.05 versus sh-NC group (empty vector); \*\*p \< 0.01 versus sh-NC group (empty vector); ^\#^p \< 0.05 versus sh-TDP43 group; ^&^p \< 0.05 versus sh-SNHG12 group). (B) Western blot analysis of SOX5 regulated by miR-195 is shown using GAPDH as endogenous control. Data are presented as the mean ± SD (n = 5 in each group). *\**p *\<* 0.05 versus pre-NC group (empty vector); ^*\#*^p *\<* 0.05 versus anti-NC group (empty vector). (C) Western blot analysis of SOX5 regulated by SNHG12 and miR-195 is shown using GAPDH as endogenous control. Data are presented as the mean ± SD (n = 5, each group). *\**p *\<* 0.05 versus sh-NC+pre-NC group (empty vectors). (D) The predicted miR-195 binding site in SOX5 (SOX5-WT) and the designed mutant sequence (SOX5-Mut) were indicated. (E) Luciferase reporter assay of HEK293T cells co-transfected with SOX5-WT or SOX5-Mut and miR-195or the miR-195-NC. Data are presented as the mean ± SD (n = 5 in each group). *\**p *\<* 0.05 versus SOX5-WT+pre-NC group.

To further support our hypothesis that SOX5 was a direct target of miR-195, we conducted dual-luciferase gene reporter assays to clarify the interaction between SNHG12 and miR-195. As shown in [Figure 5](#fig5){ref-type="fig"}E, luciferase activity in the SOX5-WT+pre-miR-195 group was significantly decreased compared with that in the control group, whereas SOX5-Mut groups were not affected. These results suggested that miR-195 targeted the specific sequence of SOX5.

Inhibition of SOX5 Largely Reverses Anti-miR-195-Induced Oncogenic Function in Glioma Cells {#sec2.7}
-------------------------------------------------------------------------------------------

To determine whether SOX5 was functionally involved in miR-195-induced regulation of glioma cells progression, we established glioma cells stably expressing anti-miR-195+sh-SOX5. As shown in [Figure 6](#fig6){ref-type="fig"}A, anti-miR-195 increased cell proliferation compared with the anti-NC group. Further, anti-miR-195+sh-SOX5 reversed anti-miR-195-induced promotion on the proliferation of glioma cells. Moreover, glioma cells treated with anti-miR-195 exhibited a lower apoptosis ratio than that in the anti-NC group ([Figure 6](#fig6){ref-type="fig"}B). Transwell assays indicated that anti-miR-195 decreased cell migration and invasion abilities, whereas sh-SOX5 rescued impairment of migration and invasion abilities induced by anti-miR-195 ([Figure 6](#fig6){ref-type="fig"}C). Similarly, sh-SOX5 increased the suppressive effect on apoptosis ratio of glioma cells promoted by anti-miR-195. Gelsolin expression was measured in cells treated with anti-miR-195 and anti-miR-195+sh-SOX5 ([Figure 7](#fig7){ref-type="fig"}B). As shown in [Figure 7](#fig7){ref-type="fig"}E, inhibition of miR-195 significantly reduced Gelsolin expression compared with the anti-NC group, while knockdown of SOX5 rescued the effect.Figure 6SOX5 Was Involved in miR-195-Mediated Tumor-Suppressive Function in Glioma Cells(A) CCK-8 assays were performed on U87 and U251 cells with the altered expression of miR-195 and SOX5. Data are presented as the mean ± SD (n = 5 in each group). *\**p *\<* 0.05 versus sh-NC group (empty vector); ^*\#*^p *\<* 0.05 versus anti-NC+sh-NC group (empty vectors). (B) Flow cytometry analysis of U87 and U251 cells with the altered expression of miR-195 and SOX5. (C) Quantification number of migration and invasion cells treated with anti-miR-195 and sh-SOX5. Representative images and accompanying statistical plots were presented. Scale bars represent 40 μm. Data are presented as the mean ± SD (n = 5 in each group). *\**p *\<* 0.05 versus anti-NC group (empty vector); ^*\#*^p *\<* 0.05 versus anti-NC+sh-NC group (empty vectors).Figure 7Gelsolin Was a Downstream Gene in the SNHG12/miR-195/SOX5 Axis, and SNHG12 Expression Was Upregulated by SOX5(A) Western blot analysis of Gelsolin regulated by SNHG12 is shown using GAPDH as endogenous control. Data are presented as the mean ± SD (n = 5 in each group). *\**p *\<* 0.05 versus sh-NC group (empty vector). (B) Western blot analysis of Gelsolin regulated by miR-195 is shown using GAPDH as endogenous control. Data are presented as the mean ± SD (n = 5 in each group). *\**p *\<* 0.05 versus pre-NC group; ^*\#*^p *\<* 0.05 versus pre-NC group (empty vectors). (C) Western blot analysis of Gelsolin regulated by SNHG12 and miR-195 is shown using GAPDH as endogenous control. Data are presented as the mean ± SD (n = 5 in each group). *\**p *\<* 0.05 versus pre-NC+sh-NC group (empty vectors). (D) Western blot analysis of Gelsolin regulated by SOX5 is shown using GAPDH as endogenous control. Data are presented as the mean ± SD (n = 5 in each group). *\**p *\<* 0.05 versus SOX5-NC group; ^*\#*^p *\<* 0.05 versus sh-NC group. (E) Western blot analysis of Gelsolin regulated by miR-195 and SOX5 is shown using GAPDH as endogenous control. Data are presented as the mean ± SD (n = 5 in each group). *\**p *\<* 0.05 versus anti-NC group; ^*\#*^p *\<* 0.05 versus anti-NC+sh-NC group. (F and G) SOX5 bound to the promoter of Gelsolin in U87 and U251 glioma cells. Transcription start site (TSS) was designated as +1. (F) Putative SOX5 binding sites are indicated. (G) Immunoprecipitated DNA was amplified by PCR. Normal rabbit IgG was used as a negative control. (H and J) SOX5 bound to the promoter of SNHG12 in U87 and U251 glioma cells. (H) Transcription start site (TSS) was designated as +1. Putative SOX5 binding sites are indicated. Immunoprecipitated DNA was amplified by PCR (J). Normal rabbit IgG was used as a negative control. (I) Real-time qPCR analysis for SOX5 regulating SNHG12 expression in U87 and U251 cells. Data are presented as the mean ± SD (n = 5 in each group). \*p \< 0.05 versus SOX5-NC group; ^\#^p \< 0.05 versus SOX5; ^&^p \< 0.05 versus sh-NC (empty vector).

Oncogene Gelsolin Is Involved in SOX5-Mediated Regulation of Glioma Cell Malignant Progression {#sec2.8}
----------------------------------------------------------------------------------------------

Gelsolin is characterized as an oncogene in various tumors including glioma.[@bib26], [@bib27] Using the bioinformatic database JASPAR, we identified Gelsolin as a downstream target of SOX5. Inhibition of SNHG12 reduced Gelsolin expression ([Figure 7](#fig7){ref-type="fig"}A). Further, as shown in [Figure 7](#fig7){ref-type="fig"}B, reintroduction of miR-195 impaired Gelsolin expression. Consistent with the above hypothesis, inhibition of SNHG12 combined with overexpression of miR-195 significantly decreased Gelsolin expression. Also, overexpression of SOX5 significantly upregulated Gelsolin expression compared with the SOX5^+^-NC group, whereas inhibition of SOX5 diminished Gelsolin expression compared with the SOX5^−^-NC group ([Figure 7](#fig7){ref-type="fig"}D).

Chromatin immunoprecipitation (ChIP) assays were conducted to investigate whether SOX5 could directly bind to the promoter of Gelsolin. The promoter sequence of Gelsolin was established according to the DBTSS HOME database. A putative binding region in the promoter was identified when scanning the DNA sequence in the −2,000 and +200 bp region of the transcription start site (TSS). As a negative control, PCR was conducted to amply the +1,000 bp of the putative SOX5 binding site. It was confirmed that there was a direct interaction between SOX5 and Gelsolin ([Figure 7](#fig7){ref-type="fig"}G). Also, no association was found between SOX5 and the control region.

SOX5 in Turn Promotes SNHG12 Expression via Binding to Its Promoter {#sec2.9}
-------------------------------------------------------------------

Using a bioinformatic database (JASPAR), we identified a potential binding site within the promoter region of SNHG12. To support this finding, we first detected SNHG12 expression in cells treated with altered SOX5 expression. As shown in [Figure 7](#fig7){ref-type="fig"}I, SNHG12 expression was robustly upregulated in the SOX5^+^ group compared with in the SOX5^+^-NC group (p \< 0.05). To further confirm the interaction between them, we conducted ChIP assays in glioma cells. SNHG12 promoter sequence was also established according to the DBTSS HOME database. The results corroborated that SOX5 directly bound to SNHG12 promoter ([Figure 7](#fig7){ref-type="fig"}J).

TDP Inhibition Combined with SNHG12 Inhibition and Overexpressed miR-195 Reduces Tumor Growth *In Vivo* {#sec2.10}
-------------------------------------------------------------------------------------------------------

*In vivo* experiment was conducted to further confirm the above findings. As shown in [Figure 8](#fig8){ref-type="fig"}A, sh-TDP43, sh-SNHG12, pre-miR-195, or sh-TDP43+sh-SNHG12+pre-miR-195 led to smaller tumor volumes than the control group. Besides, TDP43 inhibition combined with SNHG12 inhibition and pre-miR-195 restoration produced the smallest tumor volume. Further, the survival analysis showed that SNHG12 inhibition, miR-195 restoration, or SNHG12 inhibition combined with miR-195 restoration led to longer survival than the control group ([Figure 8](#fig8){ref-type="fig"}C).Figure 8*In Vivo* Study(A) The stable expressing cells were used for the *in vivo* study. The nude mice carrying tumors from respective groups are shown. The sample tumors from respective groups are shown. (B) Tumor volume was calculated every 4 days after injection, and the tumor was excised after 44 days. \*p \< 0.05 versus control group; ^\#^p \< 0.05 versus sh-TDP43 group; ^▲^p \< 0.05 versus sh-SNHG12 group; ^&^p \< 0.05 versus sh-SNHG12 group. Each \* is a single group compared to the control group. (C) The survival curves of nude mice with xenografts injected into the right striatum (n = 15). p \< 0.05 (sh-TDP43, sh-SNHG12, or pre-miR-195 versus control group); p \< 0.01 (sh-TDP43+sh-SNHG12+pre-miR-195 group versus control group).

High Expression of TDP43 and SNHG12 or Low miR-195 Expression Are Associated with Poor Prognosis of Glioma Patients {#sec2.11}
-------------------------------------------------------------------------------------------------------------------

Kaplan-Meier analysis and log rank test were conducted to analyze the effects of TDP43, SNHG12, and miR-195 on patients' survival. The overall survival rate was 17.95% (7 of 39 patients; detailed patient information was described in [Table S1](#mmc1){ref-type="supplementary-material"}). In the log rank test, results showed that patients with glioma ofTDP43-high, SNHG12-high, and miR-195-low expression tended to have poorer overall survival (log rank test, p \< 0.05; [Figures 9](#fig9){ref-type="fig"}A--9C).Figure 9Association of TDP43, SNGH12, and miR-195 Expression with Glioma Patients' Survival(A--C) Kaplan-Meier analysis and log rank test on all patients (n = 37) proved that patients with (A) TDP43-high, (B) SNHG12-high, or (C) miR-195-low expression had worse prognosis (log rank test, p \< 0.05). (D) The schematic illustration of the mechanism of TDP43/SNGH12/miR-195.

Discussion {#sec3}
==========

In the present study, we found that TDP43 and SNHG12 exhibited high expression levels in glioma tissues and cells. Inhibition of TDP43 hindered malignant biological behaviors of glioma cells via destabilizing SNHG12. Moreover, miR-195 exhibited low expression level in glioma tissues and cells. In contrast with TDP43 and SNHG12, knockdown of miR-195 facilitated cell proliferation, migration, and invasion, whereas it inhibited apoptosis of glioma cells. miR-195 targeted SNHG12 in a sequence-specific manner. SNHG12 and miR-195 were in an RISC complex. Mechanistically, knockdown of SNHG12 reduced SOX5 expression through downregulating miR-195, which could negatively regulate SOX5 expression by targeting its 3′ UTR. SOX5 exerted oncogenic function by promoting oncogene Gelsolin expression. Interestingly, in turn, SOX5 upregulated SNHG12 expression by binding to its promoter region. Remarkably, inhibition of TDP43 combined with inhibition of SNHG12 and restoration of miR-195 largely reduced xenograft tumor growth and prolonged the nude mice survival.

Accumulated evidence has proven dysregulation of RBPs is involved in regulating tumor cells biological process. In colorectal cancer, RBP polypyrimidine tract-binding protein 1 (PTBP1) is overexpressed. Knockdown of PTBP1 expression hindered the invasion of colorectal cancer cells via alternative splicing of cortactin.[@bib28] In addition, HuR binds with OIP5-AS1 in HeLa cells and stabilizes OIP5-AS1.[@bib29] TDP43 expression is upregulated in non-small-cell lung cancer (NSCLC) cells. Inhibition of TDP43 attenuates migration and invasion of NSCLC cells by decreasing lncRNA MALAT1 expression.[@bib30] However, the detailed molecular function of TDP43 modulating lncRNA has not been investigated. Our results showed that TDP43 was highly expressed in glioma tissues and cells. Inhibition of TDP43 inhibited malignant biological behaviors of glioma cells. More importantly, we found that knockdown of TDP43 decreased SNHG12 expression by reducing SNHG12's half-life.

Emerging evidence has confirmed that lncRNAs are dysregulated in various tumor cells and played pivotal functions in diverse cellular process. In this regard, it is urgent to ascertain the dysregulated lncRNAs and the underlying mechanism in tumors. lncRNA taurine upregulated 1 (TUG1) favors tumor-induced angiogenesis through upregulating vascular endothelial growth factor A (VEGFA) in human glioma.[@bib31] Meanwhile, reintroduction of lncRNA GAS5 impairs proliferation, migration, and invasion, while it promotes apoptosis of human glioma cells.[@bib32] An earlier study has shown that SNHG12 exerts oncogenic function in human osteosarcoma cells.[@bib8] Moreover, aberrant expressed SNHG12 might be involved in regulation of brain microvascular endothelium after cerebral ischemia.[@bib33] Therefore, we hypothesized that SNHG12 was dysregulated and played crucial roles in human glioma cells. As expected, our results showed that SNHG12 was upregulated in glioma tissues and cells, and promoted malignant progression of glioma cells. However, the underlying mechanism still remains unclear.

miR-195 has been proved to be downregulated in glioma tissues, and it inhibits tumor growth and invasion.[@bib18] But one research study also demonstrated that it was upregulated together with TGF-β1.[@bib34] We further examined the expression and location of miR-195 in glioma cells and the detailed function exerted by miR-195. Our results indicated miR-195 was downregulated in glioma cells. Restoration of miR-195 inhibited proliferation, migration, and invasion, while facilitating apoptosis of glioma cells. It was downregulated via cyclosporine A to further inhibit the malignancy of human glioblastoma cells.[@bib35] Our findings suggested miR-195 was a tumor suppressor in human glioma. Consistent with our findings, earlier reports proved miR-195 plays tumor-suppressive function in various tumors. For example, miR-195 is downregulated in human prostate cancer, and it impairs malignant progression of prostate cancer cells by decreasing BCOX1 expression.[@bib36] Overexpression of miR-195 hinders proliferation and metastasis of NSCLC cells through targeting CHEK1.[@bib37] More importantly, earlier studies have proven miR-195 can inhibit proliferation and invasion of human glioma cells, and is involved in temozolomide resistance.[@bib38] However, the suppressive function of miR-195 in glioma cells remains unclear.

The above findings suggested SNHG12 and miR-195 had opposite function in glioma cells. miR-195 expression was negatively correlated with SNHG12 expression. Further, bioinformatics databases and luciferase assay results supported the hypothesis that there was a binding site of SNHG12 and miR-195. Besides, we found SNHG12 and miR-195 were in the RISC complex. Also, knockdown of miR-195 reversed suppression of glioma cell progression induced by inhibition of SNHG12. More importantly, knockdown of SNHG12 combined with miR-195 significantly reduced xenografts tumor growth. Accumulating evidence has shown similar regulatory mechanism between lncRNAs and miRNAs. lncRNA UCA1 acts as an endogenous sponge and downregulates miR-143 in an RISC manner in breast cancer.[@bib39] Similarly, miR-21 targets GAS5 in a sequence-specific manner, and miR-21 and GAS5 are in a RISC complex.[@bib40] The same negative correlation and regulation mechanism exists in some other lncRNAs/miRNAs as well, such as NEAT1/miR-377, ATB/miR-200a, and NRF/miR-873.[@bib41], [@bib42], [@bib43]

Earlier findings have confirmed a manner where miRNAs are involved in regulation of cellular process via targeting the 3′ UTR of downstream genes. miR-205 modulates resistance to docetaxel in breast cancer cells through directly targeting VEGFA and fibroblast growth factor 2 (FGF2) 3′ UTR.[@bib44] In osteosarcoma cancer stem cells, miR-26a attenuates cell growth by directly binding to Jagged1 mRNA 3′ UTR.[@bib45] In the present study, SOX5 was identified as a target of miR-195. To examine this, we detected SOX5 expression in cells treated with pre- or anti-miR-195. Our results showed that overexpression of miR-195 decreased expression of SOX5. Luciferase assay further confirmed miR-195 targeted SOX5 3′ UTR in a sequence-specific manner. Moreover, knockdown of TDP43 and SNHG12 reduced SOX5 expression, suggesting SOX5 was involved in TDP43-mediated regulation of glioma cell progression. In most cases, SOX5 acts as an oncogene in various tumors such as NSCLC, hepatocellular carcinoma, and glioma.[@bib25], [@bib46], [@bib47] An earlier report has shown that SOX5 is a frequent tumor antigen in glioma and is related to diagnosis and prognosis in glioma patients.[@bib25] Our results showed that SOX5 was upregulated in glioma tissues and cells. Therefore, we hypothesized SOX5 might exert a crucial role in glioma progression. To validate our hypothesis, we examined the effect of downregulation of SOX5 on glioma cells. As expected, inhibition of SOX5 attenuated cell proliferation, migration, and invasion, while promoting apoptosis of glioma cells. However, the underlying mechanism in which SOX5 regulates glioma cell progression needs to be further explored.

SOX5 is identified as a transcription factor and exerts its role by modulating downstream genes expression. In most cases, SOX5 transactivates downstream genes via binding to their promoters. For instance, SOX5 facilitates malignant progression of breast cancer cells through upregulating Twist.[@bib47] Similarly, SOX5 upregulates Catsper1 gene expression by interacting with its promoter.[@bib48] Gelsolin was identified as a downstream protein of SOX5 using JASPAR and might be modulated by SOX5. Our results showed that overexpression of SOX5 activated Gelsolin expression, whereas inhibition of SOX5 produced the opposite effect. Further, ChIP assay confirmed that SOX5 directly bound to the specific sequence in the promoter of Gelsolin. In addition, inhibition of SNHG12 or overexpression of miR-195 led to decreased expression of Gelsolin, suggesting Gelsolin was involved in SNHG12/miR-195-mediated regulation of glioma cells. Gelsolin is characterized as an actin-binding protein and favors malignant progression of multiple tumor cells such as non-small lung cancer, gastric carcinoma, and glioma.[@bib27], [@bib49], [@bib50] More importantly, several reports have indicated that Gelsolin facilitates tumor cells progression by regulating various cellular key pathways, including phosphatidylinositol 3-kinase (PI3K)/Akt and mitogen-activated protein kinase (MAPK).[@bib50], [@bib51] PI3K/Akt and MAPK are two classical pathways that directly regulate cell proliferation, migration, invasion, and apoptosis. Besides, we also found SOX5 could reverse miR-195-induced downregulation of Gelsolin, indicating that Gelsolin was involved in SNHG12/miR-195-mediated promotion of glioma cell progression.

Remarkably, recent work has shown that transcription factor can regulate lncRNA expression and form a feedback loop. For instance, RUNX1 promotes glioma cell progression and is upregulated by lncRNA HCP5. Meanwhile, RUNX1 binds to the promoter of HCP5 and activates HCP5 expression.[@bib52] In pancreatic cancer, lncRNA H19 promotes cancer cell progression via upregulating the transcription factor Slug. Also, Slug upregulates H19 expression by activating its promoter.[@bib53] Our results showed that knockdown of SNHG12 decreased expression of SOX5. Using the bioinformatics software JASPAR, we identified a putative sequence in the promoter of SNHG12 that SOX5 might bind to. Then we detected the expression of SNHG12 in cells treated with altered SOX5. As the results showed, overexpression of SOX5 upregulated SNHG12 expression, whereas inhibition of SOX5 diminished SNHG12 expression. Moreover, ChIP assay confirmed SOX5 bound to the SNHG12 promoter. These results support our hypothesis that there is a positive feedback loop between SNHG12 and SOX5.

In summary, the present study revealed knockdown of TDP43 and SNHG12 inhibited cell proliferation, migration, and invasion, while it promoted apoptosis of glioma cells. miR-195 exerted tumor-suppressive function via decreasing SOX5 expression. The significance of interactions among TDP43, SNHG12, miR-195, SOX5, and Gelsolin is highlighted for the first time. In conclusion, our findings have provided a better understanding of RBP-lncRNA-miRNA-transcription factor feedback loop function in glioma progression. TDP43/SNHG12/miR-195/SOX5 may be a promising target in glioma therapy.

Materials and Methods {#sec4}
=====================

Clinical Human Tissue Specimens {#sec4.1}
-------------------------------

Informed consent was approved and obtained from all patients, and the project was approved by the Ethics Committee of Shengjing Hospital of China Medical University. For details, see [Supplemental Materials and Methods](#mmc1){ref-type="supplementary-material"}.

Cell Culture {#sec4.2}
------------

Human U87 and U251 glioma cell lines and HEK293 cells were purchased from Shanghai Institutes for Biological Sciences Cell Resource Center as previously described.[@bib54] For details, see also [Supplemental Materials and Methods](#mmc1){ref-type="supplementary-material"}.

FISH {#sec4.3}
----

FISH assays were performed as previously described.[@bib55] For characterization of SNHG12 and miR-195 rearrangement in glioma tissues and cells, SNHG12 probe (green-labeled; Biosense, Guangzhou, China) and miR-195 probe (red-labeled; Exiqon, Copenhagen, Denmark) were used. See also [Supplemental Materials and Methods](#mmc1){ref-type="supplementary-material"}.

RT-PCR and Real-Time qPCR {#sec4.4}
-------------------------

Real-time qPCR was conducted as previously described.[@bib56] TRIzol reagent (Life Technologies Corporation, Carlsbad, CA, USA) was used to extract total RNA from the clinical tissues, normal human astrocytes (NHA), U87, and U251 cells. See [Supplemental Materials and Methods](#mmc1){ref-type="supplementary-material"} for details.

Human lncRNA and miRNA Microarrays {#sec4.5}
----------------------------------

lncRNA and miRNA analysis, sample preparation, and microarray hybridization were performed by Kangchen Bio-tech (Shanghai, China).

Western Blot {#sec4.6}
------------

Western blot was performed as described earlier.[@bib57] For details, see [Supplemental Materials and Methods](#mmc1){ref-type="supplementary-material"}.

Cell Transfections {#sec4.7}
------------------

Cell transfections were performed as previously described.[@bib55] For details, see also [Supplemental Materials and Methods](#mmc1){ref-type="supplementary-material"}.

Cell Proliferation Assay {#sec4.8}
------------------------

Cell Counting Kit-8 assay (CCK-8; Dojin, Japan) was used to determine the proliferation of glioma cells. The experiment was performed as previously described.[@bib58] See [Supplemental Materials and Methods](#mmc1){ref-type="supplementary-material"} for details.

Migration and Invasion Assays {#sec4.9}
-----------------------------

Migration and invasion assays were performed as previously reported.[@bib54] 24-well chambers with 8-μm pore size (Corning, USA) were used for migration and invasion determination of U87 and U251 cells *in vitro*. See [Supplemental Materials and Methods](#mmc1){ref-type="supplementary-material"} for details.

Apoptosis Analysis {#sec4.10}
------------------

Cell apoptosis was determined by Annexin V-phycoerythrin (PE)/ 7-actinomycin D (7AAD) staining (Southern Biotech, Birmingham, AL, USA) as previously described.[@bib54] For details, see also [Supplemental Materials and Methods](#mmc1){ref-type="supplementary-material"}.

Reporter Vectors Construction and Luciferase Assays {#sec4.11}
---------------------------------------------------

The putative miR-195 binding site of SNHG12 and SOX5 3′ UTR sequences were amplified by PCR and cloned into a pmirGlo Dual-luciferase miRNA Target Expression Vector (Promega, Madison, WI, USA) to construct luciferase reporter vector (SNHG12-WT and SOX5-WT) (GenePharma). Luciferase assays were conducted as previously reported.[@bib55] For details, see [Supplemental Materials and Methods](#mmc1){ref-type="supplementary-material"}.

RNA Pull-Down Assays {#sec4.12}
--------------------

RNA pull-down assays were conducted as previously reported.[@bib59] For details, see also [Supplemental Materials and Methods](#mmc1){ref-type="supplementary-material"}.

RNA Stability Measurement {#sec4.13}
-------------------------

After transfected with sh-NC or sh-TDP43, HEK293 cells were treated with Actinomycin D (5 μg/mL final concentration) or DMSO as a control. Total RNA was collected at different time points and analyzed by real-time qPCR.

RIP {#sec4.14}
---

RIP immunoprecipitation was performed as previously described.[@bib54] See also [Supplemental Materials and Methods](#mmc1){ref-type="supplementary-material"} for details.

ChIP Assay {#sec4.15}
----------

ChIP assay was conducted with Simple ChIP Enzymatic Chromatin IP Kit (Cell signaling Technology, Danvers, MA, USA) according to the manufacturer's instruction as previously described.[@bib60] See [Supplemental Materials and Methods](#mmc1){ref-type="supplementary-material"} for details.

Tumor Xenografts in Nude Mice {#sec4.16}
-----------------------------

The tumor xenografts experiment was performed as previously described.[@bib54] Stable transfected U87 and U251 cells were used for *in vivo* study. See also [Supplemental Materials and Methods](#mmc1){ref-type="supplementary-material"} for details.

Statistical Analysis {#sec4.17}
--------------------

Data were presented as mean ± SD. All statistical analyses were evaluated by SPSS 18.0 statistical software (IBM, New York, NY, USA) with the Student's t test or one-way ANOVA as previously described. For details, see also [Supplemental Materials and Methods](#mmc1){ref-type="supplementary-material"}.
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